Krystal Biotech's (KRYS) "Buy" Rating Reiterated at HC Wainwright

Krystal Biotech (NASDAQ:KRYS - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $240.00 price objective on the stock. HC Wainwright's price objective would suggest a potential upside of 66.63% from the stock's previous close.

Other analysts have also issued reports about the company. Guggenheim dropped their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Chardan Capital reissued a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a research note on Wednesday, May 7th. Citigroup cut their price target on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a report on Friday, May 16th. Finally, Jefferies Financial Group began coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective for the company. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $211.13.

Krystal Biotech Stock Performance

Shares of KRYS traded up $6.12 during trading hours on Tuesday, hitting $144.04. The stock had a trading volume of 142,348 shares, compared to its average volume of 286,809. The firm has a 50-day moving average price of $142.73 and a 200 day moving average price of $158.68. Krystal Biotech has a fifty-two week low of $122.80 and a fifty-two week high of $219.34. The firm has a market capitalization of $4.16 billion, a price-to-earnings ratio of 34.55 and a beta of 0.66.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. The firm had revenue of $88.18 million during the quarter, compared to analysts' expectations of $98.66 million. As a group, analysts predict that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Principal Financial Group Inc. raised its holdings in shares of Krystal Biotech by 3.1% during the 4th quarter. Principal Financial Group Inc. now owns 123,453 shares of the company's stock worth $19,340,000 after acquiring an additional 3,727 shares during the period. Teacher Retirement System of Texas raised its stake in Krystal Biotech by 27.3% during the fourth quarter. Teacher Retirement System of Texas now owns 6,383 shares of the company's stock worth $1,000,000 after purchasing an additional 1,369 shares during the period. Raymond James Financial Inc. acquired a new position in Krystal Biotech in the 4th quarter valued at about $15,989,000. JPMorgan Chase & Co. boosted its holdings in Krystal Biotech by 18.7% in the 4th quarter. JPMorgan Chase & Co. now owns 151,835 shares of the company's stock valued at $23,786,000 after purchasing an additional 23,934 shares during the last quarter. Finally, Federated Hermes Inc. grew its stake in shares of Krystal Biotech by 1.8% in the 4th quarter. Federated Hermes Inc. now owns 13,048 shares of the company's stock valued at $2,044,000 after buying an additional 229 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.